Based on their mechanisms-of-action, CD20 monoclonal antibodies (mAbs) are grouped into Type I [complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)] and Type II [programmed cell death (PCD) and ADCC] mAbs. We generated 17 new hybridomas producing CD20 mAbs of different isotypes and determined unique heavy and light chain sequence pairs for 13 of them. We studied their epitope binding, binding kinetics and structural properties and investigated their predictive value for effector functions, i.e. PCD, CDC and ADCC. Peptide mapping and CD20 mutant screens revealed that 10 out of these 11 new mAbs have an overlapping epitope with the prototypic Type I mAb rituximab, albeit that distinct amino acids of the CD20 molecule contributed differently. Binding kinetics did not correlate with the striking differences in CDC activity among the mIgG2c mAbs. Interestingly, chimerization of mAb m1 resulted in a mAb displaying both Type I and II characteristics. PCD induction was lost upon introduction of a mutation in the framework of the heavy chain affecting the elbow angle, supporting that structural changes within this region can affect functional activities of CD20 mAbs. Together, these new CD20 mAbs provide further insights in the properties dictating the functional efficacy of CD20 mAbs.
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Three unconjugated CD20 monoclonal antibodies (mAbs) have been approved for the treatment of various subtypes of Non-Hodgkin lymphomas (NHL) and leukaemias. Rituximab (RTX), the first mAb on the market for malignant diseases, has significantly improved survival of patients when given in combination with a chemotherapeutic regimen (Rastetter et al, 2004; Coiffier et al, 2010; Keating, 2010; Maloney, 2012) . Ofatumumab (OFA) was selected on its outstanding ability to activate the classical complement pathway, leading to membrane disruption and complement-dependent cytotoxicity (CDC) (Teeling et al, 2004) . Clinical trials highlighted its potential in combination therapies and maintenance of, e.g. chronic lymphocytic leukaemia (CLL) patients (Sandhu & Mulligan, 2015) . Obinutuzumab (OBZ; GA101), a CD20 mAb with enhanced FccRIII (FCGR3) binding and direct programmed cell death (PCD) induction capacity, has been approved for first-line treatment of CLL and RTX-refractory follicular NHL (Goede et al, 2014) .
In vitro, CD20 mAbs can induce antibody-dependent cellmediated cytotoxicity/phagocytosis (ADCC/ADCP), CDC or PCD. Depending on their mechanisms-of-action (MoA), CD20 mAbs are grouped into Type I or Type II. Type I mAbs, including RTX and OFA, relocate CD20 into lipid rafts and efficiently activate the complement system . Both Type I and II mAbs elicit ADCC. Type II mAbs induce PCD via a caspase-independent pathway . The only described Type II mAbs are OBZ, B1 (parental Ab of the radioimmunoconjugate tositumomab) and 11B8 (Teeling et al, 2004; Beers et al, 2008; Mossner et al, 2010) . Interestingly, RTX was shown to induce PCD via the same pathway in lymphoma cell lines and primary CLL cells, but to a lower extent than Type II mAbs (Stanglmaier et al, 2004) . Also 2B8, the murine parental Ab of the US Food and Drug Administration (FDA)-approved CD20-specific radioimmunoconjugate ibritumomab and RTX, has the capacity to induce apoptosis (Uchiyama et al, 2010) . More recently, CD20 mAbs displaying both Type I and Type II characteristics in vitro were described (Li et al, 2009; Bornstein et al, 2010; Nishida et al, 2011) .
In the literature, three features were suggested to govern Type I/II classification: (a) the epitope, (b) binding kinetics and (c) residues within the elbow angle determining region of the variable heavy (VH) chain framework (Boross & Leusen, 2012) .
Human CD20 comprises a small (residue 72-80) and larger (residue 140-186) extracellular loop. The epitope of the Type I mAbs RTX, veltuzumab and ocrelizumab is located on the larger loop, with 170 ANPS 173 representing the core binding region and N171 as the key residue for RTX binding (Polyak & Deans, 2002; Teeling et al, 2006; Du et al, 2007; Niederfellner et al, 2011; Klein et al, 2013a) . OBZ and B1 share an overlapping epitope ( 170 ANPSEKNSP
178
) with RTX, with residues 176-178 contributing the most, but are Type II mAbs. Next, the epitope of the Type I mAb OFA and Type II mAb 11B8 is comprised of residues on the small and larger loop (Teeling et al, 2006) . These similarities between Type I and Type II mAbs already indicate that the epitope is not decisive for Type I/II classification.
However, Ab kinetics were suggested to correlate with the CDC activity of CD20 mAbs, as the strong complementinducing mAbs OFA and veltuzumab dissociate significantly slower from CD20 than RTX, which has an intermediate CDC capacity (Teeling et al, 2004; Goldenberg et al, 2010) . Next to antigen binding properties, a structural Ab feature was suggested to determine the Type I/II classification. During the humanisation of B-Ly1 (Type I) to OBZ (Type II) a L11V mutation was introduced in the heavy chain framework. The replacement of valine with a leucine in the OBZ sequence resulted in loss of its PCD induction capacity (Mossner et al, 2010) . Modelling indicated that the presence of a valine residue results in a wider elbow angle for OBZ (167°) compared to the leucine residue as in RTX (140°) (Niederfellner et al, 2011) .
Due to the limited number of CD20 mAbs, drawing conclusions about which properties determine the MoA of CD20 mAbs has been difficult. Here, we generated and functionally characterized a panel of novel CD20 mouse IgG (mIgG) mAbs. All these mouse mAbs displayed Type I characteristics. In particular, among the new CD20 mAbs, some induced CDC more potently than the FDA-approved mAbs, RTX and OFA. The 4 mIgG2c-CD20 mAbs, differing in their functional in vitro characteristics, were all effective in an in vivo model. Interestingly, upon chimerization of a subpanel of the CD20 mAbs, one mAb displayed Type II properties. Moreover, the ability of this mAb to induce PCD was lost upon insertion of the L11V mutation within the elbow angle determining region, which was previously shown to be of importance for the Type II properties of OBZ. Collectively, the data support the notion that neither the epitope, nor the off-rate solely dictates Type I/ II classification, but the elbow angle is of importance.
Materials and methods

Antibodies
CD20 mAbs were generated by cellular immunization and standard fusion of spleen cells to obtain hybridomas. mAbs were purified after growth in serum-free medium by affinity chromatography using HiTRaprProteinA FF columns (GE Healthcare, Hoevelaken, The Netherlands). Isotypes were determined by fluorescence-activated cell sorting (FACS) [ratanti-mIgG2a-biotin (cross-reactive with mIgG2c; Becton Dickinson (BD), San Jose, CA, USA)], goat-anti-mIgG2b-Fcc-RPE (SouthernBiotech, Birmingham, AL, USA), goat-anti-mIgG3-PerCP (Jackson, Bar Harbor, ME, USA)]. Chimeric IgG1-CD20 (IgG1) mAbs were generated using Lonza expression vectors (pEE14Á4-kappaLC, pEE14Á4-IgG1). The L11V mutation was introduced into the heavy chain by site-directed mutagenesis. All IgG1-CD20 mAbs were produced by transient transfection of HEK293F cells and purified by ProteinA affinity chromatography (Meyer et al, 2016) .
Control CD20 mAbs: RTX (chimeric IgG1) and OFA (human IgG1) (both Pharmacy UMC Utrecht, Utrecht, The Netherlands); IgG1-CD20-11B8 (11B8), mIgG2a-CD20-7D8 (m7D8) and mIgG2a-CD20-11B8 (m11B8) (kindly provided by Genmab, Utrecht, The Netherlands); B1 (mIgG2a, kindly provided by Mark Cragg, University of Southampton, Southampton, UK); mIgG2a-RTX (mRTX) (Invivogen, San Diego, CA, USA). mAbs were labelled with fluorescein isothiocyanate (FITC; Thermo Fisher Scientific, Waltham, MA, USA) or Alexa647 (Molecular Probes, Eugene, OR, USA) following the manufacturer's instructions. mAbs were dialysed to phosphate-buffered saline (PBS; Sigma-Aldrich, Zwijndrecht, The Netherlands) and the concentration determined using the following formula: OD 280 nm /correction factor (mIgG 1Á36; human/chimeric IgG 1Á35).
Cell lines
SKBR3-CD20 and EL4-CD20 cells [American Type Culture collection (ATCC), Manassas, VA, USA] were generated by retroviral transduction as described before (DiGaetano et al, 2003) . Daudi, Ramos (ATCC), and the above-mentioned cell lines were cultured in RPMI-1640 + HEPES + glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 lg/ml streptomycin (Life Technologies, Carlsbad, CA, USA) at 37°C/5% CO 2 . FreeStyle TM HEK293F cells (Invitrogen) were cultured in FreeStyle TM 293 expression medium (Invitrogen) at 37°C/8% CO 2 on an orbital shaker. Determination of consensus amino acid sequence of variable regions Hybridoma RNA was isolated and purified using a RNeasy mini kit (Qiagen, Hilden, Germany). Next, variable light (VL) and variable heavy (VH) regions were amplified by polymerase chain reaction (PCR). Gel-purified PCR products were cloned into the pCRII blunt TOPO vector (Life Technologies) and transformed into DH5a E. coli. Plasmid DNA was isolated from several clones using a QIAprep spin miniprep kit (Qiagen). Subsequently, consensus DNA sequences of VL and VH regions from each mIgG-CD20 mAb were determined by DNA sequencing (Macrogen, Amsterdam, The Netherlands) of several plasmid clones containing insert. Based on the sequence information of several clones of each mAb, the consensus V-region sequences were determined and the amino acid sequences deduced. Sequence alignments were determined using Jalview (Waterhouse et al, 2009 ).
Mutant screen
HEK293F cells were transfected with vectors coding for wildtype or mutated CD20 using 293fectin (Invitrogen) following the manufacturer's instructions. One day post-transfection, cells were harvested, washed in FACS buffer and stained for 30 min with 5 lg/ml CD20 mAbs on ice. mAb binding was detected with a goat-anti-hIgG-APC or goat-anti-mIgG-APC Ab (Jackson). Cells were measured on a FACS Canto II (BD).
CD20 peptide library design and screen
The design of the CD20 peptide library was described elsewhere (Teeling et al, 2006) . Briefly, both linear and cyclic peptides, with loops of different sizes, covering the 2 extracellular loops were directly synthesized onto polypropylene plates (Slootstra et al, 1996; Timmerman et al, 2005) . Linear and discontinuous epitopes were reconstructed, and for each peptide a positional amino acid scan was included. Recognition of peptides by the CD20 mAb was assessed in a PepScan-based enzyme-linked immunosorbent assay (ELISA) as previously described (Teeling et al, 2006) . 1 lg/ml mAb was added to plates with covalently linked peptides and incubated overnight at 4°C. After extensive washing, bound mAb was detected with a horseradish peroxidase-linked rabbitanti-mIgG (DakoCytomation, Glostrup, Denmark) for 1 h at 25°C. Unbound detection Ab was washed away. Plates were developed using 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate and colour development quantified using a charge-coupled device (CCD) camera and an image-processing system.
Ligand tracer
Kinetics analysis of interactions between the mAbs and CD20 was performed by using the LigandTracer Technology (Ridgeview Instruments AB, Uppsala, Sweden). Association of 10 nmol/l FITC-labelled CD20 mAb to SKBR3-CD20 was measured followed by a non-competitive (culture medium) or competitive (100 nmol/l unlabelled mAb of the same clone) dissociation. Analysis was performed using a OneToOne fitting model in TraceDrawer (Ridgeview Instruments AB).
Homotypic aggregation and cell viability assays
EL4-CD20 cells (0Á4 9 10 5 ) together with 1 lg/ml mAb in culture medium were plated out in a 96-well plate, and incubated for 24 h at 37°C/5% CO 2 . In the cross-linking conditions the following Abs were added 30 min later: 20 lg/ml rabbit-F(ab') 2 -anti-hIgG (Jackson) or 50 lg/ml rabbit-F(ab') 2 -anti-mIgG (Jackson). Homotypic aggregation was assessed semi-quantitatively using an EVOS â microscope (209 magnification). Cell viability was determined by AnnexinV-phycoerythrin (PE) staining or with DiOC6 and TO-PRO-3 staining (Thermo Fisher Scientific), following the manufacturer's instructions.
CDC assay
10 5 cells (Daudi, Ramos, Raji) were plated out in a 96-well plate and pre-incubated for 30 min at room temperature with mAb diluted in culture medium. Human serum (pooled from 8 healthy donors) as complement source (final concentration 15Á5%) was added and the preparation kept for 15 min at 37°C/5% CO 2 . The degree of complementmediated lysis was assessed by staining dead cells with 7-AAD (BD Pharmingen, San Jose, CA, USA). Cells were measured on a FACS Canto II (BD).
Human peripheral blood mononuclear cells (PBMC) ADCC
PBMC isolated from healthy individuals by Ficoll separation (GE Healthcare) were combined with 51 Cr-labelled Daudi cells (effector-to-target ratio = 100:1) and CD20 mAb in dilution. After 4 h incubation at 37°C/5% CO 2, the supernatant was harvested and counted in a liquid scintillation counter (MicroBeta; Perkin Elmer, Waltham, MA, USA). Lysis was calculated using the following formula: % lysis = [(counts of sample -minimum release)/(maximum release -minimum release)] 9 100. Daudi cells with PBMC in culture medium or in medium supplemented with 2Á5% Triton X-100 (Roche Diagnostics, Almere, The Netherlands) were used to determine minimum and maximum release, respectively.
EL4-CD20 lymphoma model
In vivo evaluation was performed using the EL4-CD20 low tumour-burden model as previously described (Boross et al, 2011) . C57BL/6 mice were purchased from Janvier (Le Genest-Saint-Isle, France) or bred in our facilities. 4-6 mice/ group were injected intraperitoneally (i.p.) with 5 9 10 5 CellTraceViolet (10 lmol/l, Invitrogen)-labelled EL4-CD20 cells. After 16 h, mice were treated with mAb or PBS (100 ll) injected i.p. A peritoneal lavage with PBS containing 5 mmol/l EDTA was performed after 24 h and the amount of remaining tumour cells was determined using TruCount tubes (BD). All experiments were approved by the Animal Ethical Committee of the UMC Utrecht.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism software 6Á0 (GraphPad Software, La Jolla, CA, USA). All tests were two-sided, and P < 0Á05 was considered statistically significant.
Results
We generated a panel of novel CD20 mAbs and characterized them in detail. After fusion of spleen B cells from 6 mice we obtained 17 stable hybridoma clones producing mIgG2c, mIgG2b and mIgG3 CD20 mAbs (Table I ). For 13 out of 17 CD20 mAbs, we retrieved unique VH and VL chain sequence pairs with differing degrees of relatedness (Fig 1) . Comparison of the new mIgG-CD20 mAbs with available Type I and II CD20 mAbs revealed that the complementary-determining region (CDR) 3 of the VH chain is the least conserved (27-63% identity for new mIgG-CD20 mAbs compared to RTX). From this panel, 11 CD20 mAbs were purified for further studies. Their binding was comparable to Type I CD20 mAbs m7D8 (derived from same panel as OFA with comparable properties but expressed as mIgG2a mAb (Teeling et al, 2004) ) and mRTX ( Figure S1 ).
New CD20 mAbs with overlapping, but distinct epitopes
In order to determine the epitopes of the newly generated CD20 mAbs we used HEK293F cells transiently expressing CD20 mutants. First, we performed a rough epitope mapping experiment with two CD20 mutants, with amino acids mutated in either the small (T159K/N163D/N166D = KDD) or larger (A170S/P172S = A 9 P) loop of CD20 (Fig 2A) . None of the new CD20 mAbs showed an impaired binding upon mutations in the binding region of m7D8 (T159K/ N163D/N166D Fig 2B) . All 11 evaluated CD20 mAbs showed distinct binding patterns. None of the 11 new CD20 mAbs showed loss of binding upon mutations of N176 or E174, two residues found to impact binding of the Type II mAbs B1 and 11B8, respectively. The binding of m9 remained untouched by any mutant. All other new CD20 mAbs showed an impaired binding to the CD20 molecule upon mutation of N171, as seen for mRTX. The two single mutants A170P and P172A made it possible to identify the contributing amino acids within the A170S/P172S double-mutant. The A170P mutation did not affect mAb binding. In contrast, the P172A mutant influenced binding of all new CD20 mAbs, except for m2, m9 and m11. Residue S173 was identified to be important for the binding of mRTX, m1, m4 and m10. Overall, the epitope of most of the new CD20 mAbs can be narrowed down to 170 ANPSE 174 , with a different level of contribution for some amino acids. Thirdly, detailed epitope mapping was performed for both mIgG2c-CD20 mAbs m1 and m2, by using PepScan technology. We identified the critical residues of m1 to be 168 EPANP-SEK 175 by using linear ( Figure S2A ) and circular (Fig 2C, left) peptides with a positional amino acid scan covering the larger extracellular loop. Also for m2, a signal decrease below the WT binding signal occurred within the 168 EPANPSEK 175 sequence motif but the binding signal to the linear ( Figure S2B ) and circular (Fig 2C, right) peptide was rather low. This suggests that the epitope of both mAbs is located on the larger loop in the same region, however their binding characteristics are different. The data suggests that m1 binds a linear epitope, whereas m2 binds to a conformational epitope.
CD20 mAbs show variation in binding stability
A slow Ab off-rate might favour the formation of Ab-C1q complexes, the first component of the classical complement pathway. FACS-based dissociation assays hinted at a unique dissociation behaviour of m1 and m2 ( Figures S3A,B) , suggesting a faster off/on-rate for m2. To characterize interaction kinetics and affinity of mAbs, we used the LigandTracer technology to record real-time binding and dissociation of our CD20 mAbs to CD20. As adherent cells expressing the target antigen were required for this analysis, we retrovirally transduced SKBR3 cells with the WT CD20 sequence. We performed kinetic analyses for all 4 mIgG2c-CD20 mAbs under non-competitive conditions ( Fig 3A) and a competitive approach (Fig 3B) , mimicking the likely over-saturation during treatment of patients with mAbs. All mAbs had a similar apparent affinity in the low to sub-nanomolar range (Table S1 ). Binding rate constants were comparable for all mAbs. The major difference in kinetics was observed in the dissociation phase. OFA, m9 and m10 dissociated very slowly, while m1, m2 and RTX had a more pronounced biphasic release [determined by InteractionMap (Ridgeview Instruments AB) analysis; data not shown]. Also, except for m9, dissociation under competitive conditions was faster than under non-competitive conditions (Fig 3C) , indicating that upon release of one epitope, mAbs are still bound or rebind to the cell under non-competitive conditions. This occurs, for example, when other receptors are in close proximity or when mAb binding is stabilized by multivalent binding, such as in mAb-(CD20) 2 complexes. m2 has the largest fraction of fast releasing mAbs and dissociation is most affected by competition. The formation of more stable complexes is due to multiple interactions, substantiated by a stronger impact of competition during long incubation times on the release of labelled mAb ( Figures S3C,D) .
New CD20 mAbs exhibit Type I characteristics Figures S4A, B) CD20 mAbs in the absence of a crosslinking Ab. Remarkably, CDC activity, the MoA only elicited by Type I mAbs, differed considerably amongst the CD20 mAbs (Figure S4C) . We analysed the CDC capacity of the mIgG2c mAbs over a wider concentration range on Daudi cells, a cell line sensitive for complement-mediated lysis due to high CD20 and low complement-regulatory protein expression (Fig 4B) . m1 and m9 showed the highest CDC activity, m10 displayed intermediate CDC potency and m2 was the least potent. Furthermore, all tested CDC-inducing mIgG2c-CD20 mAbs segregate antigen into lipid rafts, a known Type I (A) Most of the new CD20 mAbs have unique heavy and light chain sequences. Sequences coding for the variable region of the (A) heavy chain and (B) light chain were aligned and compared with commercially available CD20 monoclonal antibodies (mAbs; blue: human mAbs; green: chimeric mAbs) by calculating the average distance using % identity (PID) based on a consensus sequence generated by the alignment program. Residues coloured according to PID (dark blue >80%, mid blue >60%, light blue >40%, white ≤40%). -represent gaps. CDRs (1-3 of heavy and light chain correspondingly) are indicated by boxes according to Kabat system. hallmark ( Figure S4D ). The better CDC induction by m1 compared to m2 was also detected in assays with Ramos and Raji cells, which have lower CD20 and higher complementregulatory protein expression ( Figure S4E ). Finally, as a shared feature of Type I and II mAbs, we determined specific cell lysis in an ADCC assay using Daudi cells as targets and PMBC as effectors. A comparable degree of lysis was obtained with all mIgG2c-CD20 mAbs (Fig 4C) . In contrast, mIgG2b mAbs were less effective ( Figure S4F ).
New CD20 mAbs exhibit variation in anti-tumor response in vivo
As mIgG2c-CD20 mAbs were the most potent in vitro, we decided to study their in vivo potency in a short low tumour burden model, previously established in our laboratory (Boross et al, 2011) . In this model, CDC was shown to be the dominant effector mechanism for tumour cell eradication. As m1 and m2 displayed the biggest differences in vitro, we used these two mAbs first to determine the effective mAb concentration (Fig 5A) . A clear concentration-dependent anti-tumour response was observed, and at 1 lg mAb a complete clearance of the tumour cells was achieved with m1 but not m2. Testing the efficacy of the remaining mIgG2c mAbs at 1 lg, m9 and m10 performed comparable to m1 (Fig 5B) .
Chimerization can impact functional properties
During the humanization of B-Ly1 to OBZ, a leucine to valine mutation at Kabat position 11 in the VH chain was introduced. The insertion of a V11L mutation into the OBZ sequence resulted in the loss of its PCD capacity and narrowed its elbow angle. To evaluate whether this residue generally alters the MoA of CD20 mAbs, we introduced the L11V into the chimerized versions of m1 (IgG1-CD20-1) and m2 (IgG1-CD20-2). Based on these OBZ data, we assumed that this modification also resulted in the alteration of the elbow angle within our CD20 mAbs. Binding, ADCC and CDC were comparable at a saturating concentration (data not shown). To study direct effector functions, we used two staining strategies to determine the extent of mAb-mediated PCD. AnnexinV was used to assess extracellular phosphatidylserine exposure and cell death, while DiOC6/TO-PRO-3 was used to quantify loss of mitochrondrial membrane potential together with cell death. Surprisingly, in PCD assays with EL4-CD20 (Fig 6A) , Ramos (Figs 6B,C) and Daudi (Figs 6D,E) cells, IgG1-CD20-1 induced PCD, a property lost upon insertion of the L11V mutation. In contrast, for IgG1-CD20-2, neither the parental nor the mutated versions induced PCD (Fig 6A) . This indicates that the MoA can change upon chimerization (Table II, Fig 7) and that the elbow angle determining region plays a crucial role in this.
Discussion
For the treatment of B cell malignancies, RTX (chimeric IgG1), OFA (human IgG1) and OBZ (glycoengineered human IgG1 Fc-region for enhanced ADCC) targeting CD20 are FDA approved. In vitro they induce tumour cell killing mediated by either ADCC and CDC (Type I; RTX and OFA) or ADCC and PCD (Type II; OBZ). It is likely that certain patient groups with, for example, a less beneficial FccR genotype or different types of B-cell malignancies, might benefit from treatments with highly complement active or apoptosis inducing mAbs. In order to develop more effective CD20 therapeutic mAbs, further understanding of the underlying characteristics dictating the MoA of CD20 mAbs is important (Beers et al, 2010a) . Despite the low immunogenicity of the CD20 molecule itself, we were able to raise new CD20 mAbs using an efficient in-house developed immunization method and purified 11 mAbs for further characterization. Studying functional properties revealed that all of the new mouse CD20 mAbs exhibit Type I characteristics as they induce CDC, but not PCD. In our panel, mIgG2b was the most frequent isotype, followed by mIgG2c and mIgG3. This is indicative for more matured Abs, because mIgG2c and mIgG2b Abs are further advanced in the class switching order of the heavy chain in C57BL/6 mice (5 0 cl-c(-cc3-cc1-cc2b-cc2c-c(-ca3 0 ) (Esser & Radbruch, 1990) . The high diversity in the variable regions indicated that we raised affinity-matured CD20 mAbs. To investigate underlying properties which determine the MoA of our new mAbs, we have determined the epitope, binding kinetics and structural properties based on a mutation at Kabat position 11. Regarding the epitope, 10 out of 11 of our mAbs bound in the same region as RTX. Our data suggest that residue S173 discerns binding between our mAbs to CD20. For example, binding of m1 (linear epitope) is completely abrogated upon mutation of residue S173. In contrast, m2 binding (conformational epitope), is much less affected. This varying recognition of CD20 results in an alteration of the binding behaviour and in-depth analysis suggests that it has an impact on the capacity of the mAb to create 1 lg/ml CD20 mAb (mean + SEM). mIgG2a-CD20 mAbs B1, mRTX and m7D8 (grey) were used as controls. Results are representative of 3 separate experiments. *P < 0Á05; **P < 0Á01; ***P < 0Á001, by one way ANOVA followed by Bonferroni post-hoc analysis.
New CD20 mAbs for Insights in Mechanisms-of-Action ª 2018 John Wiley & Sons Ltd secondary interactions. Next, the C-terminal part of the larger loop of CD20 was found to be critical for B1 and OBZ binding, suggesting that this epitope is important for the Type II features of the mAbs (Niederfellner et al, 2011; Klein et al, 2013a) . However, the similar location of the epitope of OBZ and B1 is most likely an incomplete explanation, given that B-Ly1, the parental mAb of OBZ, does not display complete Type II characteristics before humanisation (Withoff et al, 2001; Umana et al, 2006) . Additionally, the epitope of Type II mAb 11B8 does not overlap with the OBZ epitope, but is comprised of amino acids located on the small and larger extracellular loop, similar to the Type I mAbs 7D8 and OFA (personal communication, P. Engelberts, Genmab, Utrecht, The Netherlands). Further, the recently suggested V11L mutation in the VH chain of OBZ, reversing the mAbs Type II characteristics, is not a universal explanation. Sequence comparison confirmed that our own Type I CD20 mAbs, and also B1 and 11B8, all carry a leucine at this position. Interestingly, the chimerized mAb derived from m1 (IgG1-CD20-1) induced PCD, a phenomenon not observed for m2. Subsequent introduction of valine at Kabat position 11 abrogated all PCD activity. This points at an involvement of the elbow angle, however we were not able to conclude if residues within the VH sequence are important, as the amino acid sequences of the VH framework around the Kabat position 11 of m1 and m2 are identical. Additionally, it would be interesting to investigate the involvement of the Kabat position 11 with B1, as next to the elbow angle, the lack of binding to N171 was implicated as a second requirement (Mossner et al, 2010) . Another attempt to modify the PCD induction capacity of CD20 mAbs was made by Konitzer et al (2015) . They showed that insertion of IgG2 and/or IgG4 CH1 and hinge region hallmark residues into the IgG1 RTX backbone results in an increase in PCD activity and altered cellular binding levels.
Concerning the binding kinetics, previous findings on the contribution of the off-rate of CD20 mAbs to CDC were contradictory. Mitigating the off-rate of RTX with a non-complement activating reagent increased its CDC activity (Teeling et al, 2004) . Also, veltuzumab, a humanised IgG1 mAb with CDRs identical to RTX except for 1 residue, displays a slower off-rate than RTX and higher CDC capacity (Goldenberg et al, 2009) . However, no CDC enhancement was induced by RTX mutants with a slower off-rate (Li et al, 2009 ). With our panel of mIgG2c-CD20 mAbs, which varied in their ability to elicit CDC, we confirmed the latter observation, as no correlation was shown between good CDC and slow dissociation, as determined in LigandTracer experiments. K D values determined using the LigandTracer technology are around 10-fold lower than the previously reported values for OFA and RTX, determined by surface plasmon resonance (Teeling et al, 2004; Li et al, 2009; Engelberts et al, 2013) . However, comparison of the obtained data remains difficult, as the methodology used differs. Further, K D values were reported to depend on the cell line used (Engelberts et al, 2013) . Overall, using the LigandTracer technology we observed the same dissociation behaviour for RTX and OFA as previously reported by FACS or radioimmunoassay assays (Goldenberg et al, 2009; Klein et al, 2013b; Bondza et al, 2017) .
More recently, it was shown that the superior CDC activity of hIgG1 mAbs is due to Fc-Fc interactions after Differences in in vivo efficacy of mouse IgG2c-CD20 mAbs. C57BL/6 mice (4-6 mice/ group) were injected intraperitoneally with 5 9 10 5 CellTraceViolet-labelled EL4-CD20 cells 16 h prior to treatment with mAb or phosphate-buffered saline (PBS). The anti-tumour response was evaluated 24 h later by determining the amount of remaining tumour cells in the peritoneal lavage with TruCount tubes. (A) mAb titration of m1, m2 and m7D8 (median AE interquartile range). (B) Anti-tumour response by 1 lg CD20 mAb, represented as % of PBS (median AE interquartile range). 1 lg m7D8 (mIgG2a) as positive control. 2 separate experiments as indicated by dashed line. *P < 0Á05; **P < 0Á01; ***P < 0Á001, by one way ANOVA followed by Bonferroni post-hoc analysis.
antigen-binding, resulting in the formation of hexamers, which facilitates C1q-binding (Diebolder et al, 2014) . Introduction of mutations strengthening the Fc-interactions in weak complement-activating mAbs resulted in enhanced CDC activity (de Jong et al, 2016) .
Our binding kinetic analyses revealed, however, divergent dissociation patterns and suggest that our CD20 mAbs differ in their ability to bind other molecules, leading to stabilization of mAb binding; whereas OFA and m10 rapidly form a stable interaction, for m1, m2 and RTX a more heterogeneous pattern was observed (Bondza et al, 2017) . The release of m2 was clearly affected by self-competition. These data point to multi-site binding of the mAbs, which differs among the panel. The fraction of mAbs that releases more quickly reduces upon increase of the incubation time.
These findings raise the question of the time dependency and type of complex formation and its effect on lipid raft formation by Type I mAbs, and eventually the influence on CDC induction. To our knowledge this has not yet been investigated.
Type I CD20 mAbs have been shown to be internalized to a larger extent than Type II CD20 mAbs, a mechanism mediated by FccRIIb (Beers et al, 2010b) . Whereas neither m1 nor m2 were internalized by that mechanism (data not shown), it remains unknown for the newly generated IgG1-CD20-1 mAb, which exhibits Type II properties.
In vitro, the new mIgG2c-CD20 mAbs could be grouped as strong (m1 and m9), intermediate (m10) and weaker (m2) complement inducers. In vivo, m1, m9 and m10 performed similarly, whereas m2 was less effective. This suggests (A) Induction of homotypic aggregation (pictures) and programmed cell death (PCD) by IgG1-CD20-1 and IgG1-CD20-2 monoclonal antibodies (mAbs) without or with the L11V mutation (1 lg/ml) in the absence or presence of crosslinking Ab (20 lg/ml anti-huIgG1; 50 lg/ml anti-mIgG) on EL4-CD20 cells. Induction of cell death was determined by AnnexinV-PE staining (mean + SEM). OFA/RTX and B1 were taken along as negative and positive controls, respectively. Results are representative of 2 separate experiments. PCD induction on (B, C) Ramos cells and (D, E) Daudi cells by IgG1-CD20-1 without or with the L11V mutation (10 lg/ml). Induction of cell death was determined by (B, D) AnnexinV-PE (AnnV) staining and (C, E) DiOC6/TO-PRO-3 staining (mean + SEM). OFA and 11B8 (grey) were taken along as negative and positive control, respectively. Results are representative of 3 separate experiments. *P < 0Á05; **P < 0Á01; ***P < 0Á001, by one way ANOVA followed by Bonferroni post-hoc analysis.
New CD20 mAbs for Insights in Mechanisms-of-Action ª 2018 John Wiley & Sons Ltd that differences detected in in vitro CDC assays were reflected by the in vivo model. CD20 mAbs are generally grouped into Type I or Type II based on their functional properties. In this study, we generated the chimerized IgG1-CD20-1 mAb, derived from m1, which efficiently induces ADCC, CDC and PCD, properties characteristic for both types. CD20 mAbs displaying shared features (also known as Type III) were described previously (Li et al, 2009; Bornstein et al, 2010; Nishida et al, 2011) . Although it was speculated that a unique epitope could be responsible for the Type III characteristics, our Type III mAb binds to the same epitope as RTX, thus this explanation is not universal (Nishida et al, 2011) . Further, the CD20 Ab 1Á5Á3 also shows Type III characteristics which could perhaps be explained by its mode of binding (Bornstein et al, 2010) . A third Type III Ab, found by Li et al (2009) , was suggested to induce a conformational change of CD20 after Ab binding, which could play a role regarding Type II or Type III characteristics (Li et al, 2009 ). We did not investigate whether our Type III mAb IgG1-CD20-1 induced such changes, but the epitope binding data do suggest it binds to a conformational epitope. To study conformational changes of the CD20 molecule itself requires the use of crystallography, which we did not pursue in the present study.
In summary, our data point to an important contribution of the elbow hinge, but exactly how this occurs remains to Overview summary of molecular determinants of existing and novel CD20 mAbs. Three distinct molecular determinants were described to determine the mechanism of action of CD20 monoclonal antibodies (mAbs): (1) epitope (positions of several CD20 mAbs are indicated); (2) kinetics (k off of the CD20 mAbs were ranked from high (10 À5 ) to low (10 À6 ), and (3) elbow angle (commercially available CD20 mAbs (OFA, RTX and OBZ) were grouped as wide or narrow angle according to the literature (Niederfellner et al, 2011; Klein et al, 2013b) . The amino acid at Kabat position 11 of the VH chain was described to influence the angle, and based on this our new chimeric mAbs were ordered according to the residue.). OBZ: obinutuzumab; OFA: ofatumumab; RTX: rituximab. be investigated. Our results provide further insights into the characteristics suggested to govern functional properties of CD20 mAbs (Fig 7) , perhaps aiding the rational design of future generations of therapeutics.
